HighTower Advisors LLC Takes Position in Drugs Made In America Acquisition II Corp. $DMII

HighTower Advisors LLC bought a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 789,614 shares of the company’s stock, valued at approximately $7,817,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DMII. Wolverine Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $10,521,000. Wealthspring Capital LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $4,049,000. Deltec Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $495,000. Finally, ABC Arbitrage SA acquired a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at $396,000.

Drugs Made In America Acquisition II Price Performance

Shares of DMII stock opened at $10.07 on Wednesday. The stock has a 50-day moving average price of $10.00. Drugs Made In America Acquisition II Corp. has a 12 month low of $9.86 and a 12 month high of $10.07.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Weiss Ratings assumed coverage on Drugs Made In America Acquisition II in a research note on Monday, March 2nd. They issued a “sell (e)” rating for the company. Wall Street Zen upgraded Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.